Ipca Laboratories Ltd Analyst Rating
based on 20 analysts
60.00%
Buy
15.00%
Hold
25.00%
Sell
Based on 20 analysts offering long term price targets for Ipca Laboratories Ltd. An average target of ₹1591.05
Source: S&P Global Market Intelligence
Ipca Laboratories Ltd Share analysis
Ipca Laboratories Ltd price forecast by 20 analysts
Upside of2.04%
High
₹1970
Target
₹1591.05
Low
₹900
Ipca Laboratories Ltd target price ₹1591.05, a slight upside of 2.04% compared to current price of ₹1589.1. According to 20 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Ipca Laboratories Ltd revenue growth forecast
Expected growth rate Q1, FY2027:46.67%
Forecast
Actual
Including amortisation and stock based compensations
Ipca Laboratories Ltd EPS growth forecast
EPS estimate Q1, FY2027:160.69%
Forecast
Actual
Source: S&P Global Market Intelligence
Ipca Laboratories Ltd Performance
Day's Low
Day's High
₹1,553Day's Price Range₹1,593.8552 Week's Low
52 Week's High
₹1,05252-Week Price Range₹1,755.9
| Returns % | |
| 1 Month Return | -1.67 % |
| 3 Month Return | -0.42 % |
| 1 Year Return | + 44.11 % |
| Market Stats | |
| Previous Close | ₹1,559.25 |
| Open | ₹1,588.25 |
| Volume | 2.26L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹39,558.83Cr |
Ipca Laboratories Ltd Key Statistics
| P/E Ratio | 59.81 |
| PEG Ratio | 8.98 |
| Market Cap | ₹39,558.83 Cr |
| P/B Ratio | 4.95 |
| EPS | 20.86 |
| Dividend Yield | 0.32 |
| Sector | Pharmaceuticals |
| ROE | 9.81 |
Ipca Laboratories Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹39,558.83 Cr | 30.85% | 0.58 | ₹529 Cr | ₹7,705 Cr | |
| BUY | ₹12,424.45 Cr | -3.71% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹69,832.16 Cr | 28.64% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹98,460.00 Cr | 52.63% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹59,020.71 Cr | 23.71% | 0.53 | NA | NA |
Ipca Laboratories Ltd Mutual Fund Holdings
About Ipca Laboratories Ltd
Share Price: ₹1589.10 per share as on 23 Jan, 2025 01:09 PM
Market Capitalisation: ₹39,558.83Cr as of today
Revenue: ₹2,354.90Cr as on September 2024 (Q3 24)
Net Profit: ₹245.44Cr as on September 2024 (Q3 24)
Listing date: 03 Nov, 1994
Chairperson Name: Premchand Godha
| Organisation | Ipca Laboratories Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Ipca Laboratories Ltd
Ipca Laboratories Set for Strong Turnaround - 14 Jan, 2025
Ipca Laboratories is expected to experience a strong turnaround driven by a revival in its US business, new product launches, and growth in ex-US markets. The company is expanding into fast-growing therapies domestically and is projected to achieve a 27% earnings CAGR over FY24-27, supported by operational efficiencies and Unichem synergies.Ipca Laboratories Stock Shows Strong Upward Potential - 08 Jan, 2025
Ipca Laboratories stock is recommended for buying at ₹1,736, with a target of ₹1,805-1,825. The stock is near its lifetime high, indicating potential for further gains.Ipca Laboratories Hits All-Time High Stock Price - 03 Jan, 2025
On January 3, 2025, Ipca Laboratories reached an all-time high of Rs. 1757.65, reflecting a 56.29% increase over the past year, significantly outperforming the Sensex. The stock has shown strong momentum with seven consecutive days of gains and is trading above key moving averages.Ipca Laboratories Hits New Highs in January 2025 - 02 Jan, 2025
On January 2, 2025, Ipca Laboratories reached an all-time high and a new 52-week high, showcasing strong performance with significant gains over six days and a remarkable annual return.Ipca Laboratories Hits New High, Positive Analyst Outlook - 01 Jan, 2025
Ipca Laboratories achieved a new 52-week high of Rs 1709.95, reflecting a 49.62% annual growth. Motilal Oswal set a target price of Rs 1980, recommending a buy. The stock rose 0.49% for the fifth consecutive session, indicating strong momentum.Ipca Laboratories Targeted for Growth and Revival - 30 Dec, 2024
Motilal Oswal has reiterated a buy rating for Ipca Laboratories with a target price of Rs 1,980, highlighting strong growth in US operations and domestic therapies. The company is expanding its divisions and expects a 27% earnings CAGR over FY24-27, driven by synergies from the Unichem acquisition.Ipca Laboratories Shows Bullish Potential - 28 Dec, 2024
Ipca Laboratories is expected to experience a significant upside, with a 92.09% rollover and a breakout on the technical front. The stock may test levels of Rs 1730 and Rs 1800 in the short term.Ipca Laboratories Focuses on Sustained Earnings Growth - 24 Dec, 2024
Ipca Laboratories is committed to maintaining strong earnings momentum over the next 2-3 years, driven by product relaunches in the US, new offerings, and synergies with Unichems.IPCA Labs Anticipates Growth and Improved Margins - 23 Dec, 2024
IPCA Laboratories expects EBITDA margins to rise to 21% due to a healthy product mix and raw material cost optimization. Strong growth in the domestic formulation business and opportunities in the API space support positive earnings outlook, with a projected stock price target of Rs 1,918 in 8 to 10 months.IPCA Labs Sees Stake Sale Amid Stock Gains - 19 Dec, 2024
IPCA Laboratories shares gained up to 6% despite a promoter selling 1.6% stake for ₹600 crore. The stock has risen 44% in 2024.Ipca Laboratories Promoter Divests 1.6% Stake - 18 Dec, 2024
Usha Madhukar Chandurkar, a promoter of Ipca Laboratories, divested a 1.6% stake for Rs 600 crore, decreasing promoter holdings from 46.3% to 44.7%. Following the sale, shares fell 2.68% to Rs 1,516.05.
Insights on Ipca Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 3 quarters, 59.59 Cr → 229.48 Cr (in ₹), with an average increase of 42.6% per quarter
- POSITIVE IMPACT
Price Rise
In the last 1 month, IPCALAB stock has moved up by 0.9%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 2.05K Cr → 2.38K Cr (in ₹), with an average increase of 7.1% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 10.83% to 11.07% in Dec 2024 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 28.55% to 29.63% in Dec 2024 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 46.6% return, outperforming this stock by 8.0%
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 103.2% return, outperforming this stock by 54.5%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 8.64% to 8.53% in Dec 2024 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 46.30% to 44.72% in Dec 2024 quarter
Ipca Laboratories Ltd Financials
Index Inclusions
Ipca Laboratories Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 44.72% | ||
| Foreign Institutions | 11.07% | 2.20 | |
| Mutual Funds | 29.63% | 3.80 | |
| Retail Investors | 8.53% | ||
| Others | 6.04% | 6.46 |
Ipca Laboratories Ltd Key Indicators
Ipca Laboratories Ltd Valuation
Ipca Laboratories Ltd in the last 5 years
Lowest (18.72x)
October 10, 2019
Industry (54.88x)
January 22, 2025
Today (59.81x)
January 22, 2025
Highest (66.90x)
January 2, 2025
Ipca Laboratories Ltd Earnings and Dividends
Ipca Laboratories Ltd Earnings Results
Ipca Laboratories Ltd’s net profit jumped 58.2% since last year same period to ₹229.48Cr in the Q2 2024-2025. On a quarterly growth basis, Ipca Laboratories Ltd has generated 19.37% jump in its net profits since last 3-months.
Read More about Earnings ResultsIpca Laboratories Ltd Dividends November,2024
In the quarter ending September 2024, Ipca Laboratories Ltd has declared dividend of ₹2 - translating a dividend yield of 0.26%.
Read More about Dividends
Ipca Laboratories Ltd Technicals Summary
Bearish
Neutral
Bullish
Ipca Laboratories Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Ipca Laboratories Ltd
Ipca Laboratories Ltd share price today stands at ₹1589.1, Open. ₹1588.25 ; Previous Close. ₹1559.25 ; High. ₹1593.85 ; Low. ₹1553 ; 52 Week High. ₹1755.9 ; 52 Week Low: ₹1052.
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Ipca Laboratories Ltd shares.
Ipca Laboratories Ltd is listed on NSE
Ipca Laboratories Ltd is listed on BSE
- Today’s highest price of Ipca Laboratories Ltd is ₹1593.85.
- Today’s lowest price of Ipca Laboratories Ltd is ₹1553.
PE Ratio of Ipca Laboratories Ltd is 59.81
PE ratio = Ipca Laboratories Ltd Market price per share / Ipca Laboratories Ltd Earnings per share
Today’s traded volume of Ipca Laboratories Ltd(IPCALAB) is 2.26L.
Today’s market capitalisation of Ipca Laboratories Ltd(IPCALAB) is ₹39558.83Cr.
| Ipca Laboratories Ltd(IPCALAB | Price |
|---|---|
52 Week High | ₹1755.9 |
52 Week Low | ₹1052 |
Ipca Laboratories Ltd(IPCALAB) share price is ₹1589.1. It is down -9.50% from its 52 Week High price of ₹1755.9
Ipca Laboratories Ltd(IPCALAB) share price is ₹1589.1. It is up 51.06% from its 52 Week Low price of ₹1052
| Ipca Laboratories Ltd(IPCALAB | Returns |
|---|---|
1 Day Returns | 29.85% |
1 Month Returns | -1.67% |
3 Month Returns | -0.42% |
1 Year Returns | 44.11% |